<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38648451</article-id><article-id pub-id-type="pmc">PMC467019</article-id>
<article-id pub-id-type="publisher-id">IJO-72-345</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_1322_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Comparison between MIGS with trabeculectomy in the management of open-angle glaucoma with cataract: A systematic review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zaifar</surname><given-names>Abritho</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pratomo</surname><given-names>Tiara Grevillea</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Suryono</surname><given-names>Astrianda Nadya</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Ophthalmology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Kirana Eye Hospital, Jakarta, Indonesia</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Tiara Grevillea Pratomo, Department of Ophthalmology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Kirana Eye Hospital, Jl. Kimia No. 8 Menteng Central Jakarta, Jakarta - 10320, Indonesia. E-mail: <email xlink:href="tiara.grevillea@gmail.com">tiara.grevillea@gmail.com</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>08</day><month>3</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S345</fpage><lpage>S353</lpage><history><date date-type="received"><day>21</day><month>5</month><year>2023</year></date><date date-type="rev-recd"><day>28</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>08</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><p>Age is an important risk factor for both glaucoma and cataract. As global life expectancy continues to rise, the prevalence of concomitant open-angle glaucoma (OAG) and cataracts is increasing. Currently, there is a lack of definitive consensus on the optimal management approach for such individuals. Conventionally, trabeculectomy (Trab) in combination with phacoemulsification is the preferred method. Recent developments in microinvasive glaucoma surgery (MIGS), which offer similar results with fewer complications, provide a new possible approach to this condition. This study aimed to assess the current knowledge of combination surgery in patients with cataract and OAG to provide a comprehensive understanding and help its implementation in clinical settings. A comprehensive systematic search was conducted in May 2021 on five databases (MEDLINE, Embase, SCOPUS, Proquest, EBSCO, and Cochrane Library). The results were filtered for English and human studies but not publication year. All studies published up to May 2021 were reviewed. Newcastle&#x02013;Ottawa Scale and PEDro scale were used to screen studies for risk of bias where appropriate. Four studies satisfied the inclusion criteria and were subsequently added in this review. Study designs consisted of one RCT and three descriptive studies. Appropriate assessment tools were used; these studies demonstrated moderate to good quality. Postoperative mean IOP, IOP reduction, and qualified success rates were comparable in the Phaco-MIGS (Phaco-endoscopic cyclophotocoagulation (ECP), Phaco-ab interno trabeculectomy (AIT)) and Phaco-Trab group. Severe complication was reported only in the latter. Phaco-MIGS (in particular, trabectome) shows excellent promise as an option for individuals with OAG and concomitant cataract; further research through RCT is required to validate these findings.</p></abstract><kwd-group><kwd>Glaucoma</kwd><kwd>glaucoma incisional surgery</kwd><kwd>intraocular pressure</kwd><kwd>microinvasive glaucoma surgery</kwd><kwd>open-angle glaucoma</kwd><kwd>phacoemulsification</kwd><kwd>trabeculectomy</kwd></kwd-group></article-meta></front><body><p>Glaucoma is a group of disorders with progressive multifactorial optic neuropathy represented by loss of neuronal tissue, excavation of the optic disc, and thinning of the nerve fiber layer.[<xref rid="R1" ref-type="bibr">1</xref>] It is the leading cause of irreversible vision loss in the world. According to the Vision Loss Expert Group of the Global Burden of Disease Study published by The Lancet, in older populations, cataracts and glaucoma were the two leading causes of blindness globally.[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref>] Around 76 million individuals aged 40&#x02013;80 years suffered from glaucoma in 2020, with a predicted constant increment in prevalence to reach 112 million individuals by 2040, affecting more people in Asia and Africa.[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref>] The main risk factor for the development and progression of the disease is intraocular pressure (IOP). Thus, the mainstay treatment of glaucoma is to reduce IOP through drugs or surgical intervention.[<xref rid="R1" ref-type="bibr">1</xref>] Primary open-angle glaucoma (POAG) is the most common subtype of glaucoma.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R5" ref-type="bibr">5</xref>] The prevalence of POAG is closely related to age, with an increased odds ratio prevalence of 1.73 for each decade increase in age.[<xref rid="R3" ref-type="bibr">3</xref>] Cataracts, the leading cause of blindness globally, also contribute largely to the prevalence of age-related eye diseases. With increasing life expectancy, their coexistence is becoming more common in the elderly population.[<xref rid="R6" ref-type="bibr">6</xref><xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref>] As aging is one of the most influencing risk factors in eye disease, the aging population will directly increase the number of people with cataracts and glaucoma.[<xref rid="R4" ref-type="bibr">4</xref><xref rid="R9" ref-type="bibr">9</xref>]</p><p>There is currently no clear consensus on the management of these concomitant diseases. From a surgical standpoint, cataract surgery may enhance aqueous drainage; however, patients are more likely to require medication postoperatively.[<xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref><xref rid="R9" ref-type="bibr">9</xref>] In addition, for patients with OAG, this might be insufficient to reach the IOP goal; thus, conventionally, phacoemulsification with trabeculectomy is the approach taken.[<xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref>]</p><p>Trabeculectomy is the gold standard of glaucoma surgical management. However, despite its effectiveness and success in reducing IOP, trabeculectomy is associated with prolonged recovery time and postoperative complications such as choroidal effusion, hyphema, bleb leak, and ptosis.[<xref rid="R12" ref-type="bibr">12</xref>]</p><p>Microinvasive glaucoma surgery (MIGS) is a novel surgical method mainly used to treat mild and moderate glaucoma by lowering the IOP with as minimum trauma as possible while avoiding the postoperative complications encountered in conventional glaucoma filtration surgery.[<xref rid="R13" ref-type="bibr">13</xref>] MIGS constitute several groups of surgical approaches that share common characteristics: high safety profile, enhanced aqueous outflow mechanism without major alteration of ocular anatomy, an ab interno approach, comparable efficacy to traditional filtering surgery, and rapid recovery with the least additional downtime.[<xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref>]</p><p>The approaches in the MIGS procedure reduce IOP through one or several of the following four mechanisms: (1) enhancing trabecular outflow, (2) ablation of the ciliary body to decrease aqueous production, (3) increased alternate pathway outflow, and (4) subconjunctival filtration.[<xref rid="R14" ref-type="bibr">14</xref>]</p><p>The trabecular meshwork offers the greatest resistance to aqueous outflow. MIGS procedure that aims to enhance trabecular outflow may do so by stenting (i.e., iStent, Hydrus) to circumvent the aqueous flow to allow direct drainage from the anterior chamber into Schlemm&#x02019;s canal, trabecular meshwork tissue excision (i.e., Trabectome), or widening of the Schlemm&#x02019;s canal. Other MIGS work to enhance aqueous outflow through the uveoscleral pathway (i.e., CyPass microstent) or into the subconjunctival space (i.e., XEN glaucoma implants). Lastly, another target for MIGS procedures to reach the IOP goal is reducing aqueous production through ciliary body ablation by using a laser unit (i.e., endocyclophotocoagulation). Compared to trabeculectomy, MIGS in conjunction with phacoemulsification may provide the same benefit with fewer complications in individuals with mild-to-moderate glaucoma and a population that does not meet the criteria of trabeculectomy.[<xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref><xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref>]</p><p>This study aimed to assess the current knowledge of combination surgery in patients with cataract and OAG to provide a comprehensive understanding and guidance in clinical practice.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><p>This systematic review was written according to the Guidelines for Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines 2020. No protocol was prepared prior to the writing of this review.</p><sec id="sec2-1"><title>Search strategy</title><p>To discover the appropriate direction for practice and treatment in POAG and cataracts, a comprehensive systematic search was done on May 5, 2021, comprising Boolean operators (AND, OR, NOT), wildcards, and truncation. The keywords used in the search process include <italic toggle="yes">microinvasive glaucoma surgery, trabeculectomy, glaucoma, iStent, Hydrus, Xen, Trabectome, endocyclophotocoagulation, micropulse, Omni, Cypass, cataract,</italic> and <italic toggle="yes">phacoemulsification.</italic> Additional filters were applied for English language studies and human studies. The systematic literature search was conducted on these databases: Medline Library, Embase, and SCOPUS-Elsevier. Grey literature was also included and searched for using Proquest and EBSCO. A manual search for additional studies was also conducted through relevant publications.</p></sec><sec id="sec2-2"><title>Eligibility criteria</title><p>Inclusion criteria were formulated using the Population, Intervention, Comparison, and Outcome (PICO) formula. The following criteria were used: adult population (&#x0003e;18 years old) with OAG and concomitant cataract in either eye undergoing a combination surgery of either phacoemulsification and trabeculectomy or phacoemulsification and MIGS, cohort, case series, case-control or randomized controlled trial study design, English as a primary language, without publication year limitation. Exclusion criteria were animal studies, case reports, conference proceedings, and review papers.</p></sec><sec id="sec2-3"><title>Data collection</title><p>Search results were documented and managed using Endnote (X9.3.3), where duplicate studies were screened and removed. Title and abstract screening of each unique article was conducted by two independent reviewers (AZ and TGP) against the established inclusion and exclusion criteria by using Covidence. Full-text reviews were then performed on the identified articles. Studies were extracted by including publication year, study design, number of participants, intervention received, length of follow-up, and success cutoff for IOP reduction. Only study participants receiving combinations of either phacoemulsification and trabeculectomy (Phaco-Trab) or phacoemulsification and MIGS (Phaco-MIGS) were reviewed and analyzed. Any disagreements were resolved through discussions among reviewers with the senior authors until a consensus was reached.</p></sec><sec id="sec2-4"><title>Critical appraisal</title><p>Included studies were examined for risk of bias by using appraisal tools. Newcastle&#x02013;Ottawa scale was employed for case series, case-control, and cohort studies, whereas the PEDro scale was employed to determine the risk of bias in RCT studies.[<xref rid="R17" ref-type="bibr">17</xref><xref rid="R18" ref-type="bibr">18</xref>] Two independent reviewers (AZ and TGP) analyzed the studies by following the tool criteria.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><sec id="sec2-5"><title>Search finding</title><p>Using the aforementioned search criteria, 1454 articles were established at first. After eliminating 598 duplicates, a total of 856 studies remained. Those studies were then filtered based on the title and abstract, and a further 796 studies were excluded because they were non-OAG study populations, review papers, case report studies, guidelines, child populations, animal studies, or irrelevant topics. The remaining 60 studies were then analyzed for full-text assessment. Subsequently, 56 studies were removed due to the following reasons: 36 studies were removed due to not having phacoemulsification and trabeculectomy combination surgery as a comparator, 19 studies were removed due to study participants not diagnosed with either cataract or OAG, and one study was removed for not having a subanalysis for the key outcome on the OAG population in the study [<xref rid="IJO.IJO_1322_23-F1" ref-type="fig">Fig. 1</xref>].</p><fig position="float" id="IJO.IJO_1322_23-F1"><label>Figure 1</label><caption><p>PRISMA flow diagram of study selection</p></caption><graphic xlink:href="IJO-72-345-g001" position="float"/></fig></sec><sec id="sec2-6"><title>Quality assessment of included studies</title><p>Quality assessments of the four included studies were done using appropriate tools in concordance with their study design. Newcastle&#x02013;Ottawa scale (NOS), as seen in <xref rid="IJO.IJO_1322_23-T1" ref-type="table">Table 1</xref>, was used to assess the risk of bias of three cohorts included in this review. The scale comprised eight questions regarding the selection of study groups, comparability, and confirmation of outcomes. In total, if all eight questions are satisfied, a maximum of nine stars could be rewarded. The cohort studies included in this systematic review were awarded 6&#x02013;9 stars, indicating a moderate to excellent quality of studies.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>]</p><table-wrap position="float" id="IJO.IJO_1322_23-T1"><label>Table 1</label><caption><p>Newcastle&#x02013;Ottawa quality assessment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="15" rowspan="1">Newcastle&#x02013;Ottawa Quality Assessment<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">Critical appraisal rating</th></tr><tr><th align="center" colspan="7" rowspan="1">Selection</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Comparability</th><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="5" rowspan="1">Outcome/Exposure</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lau <italic toggle="yes">et al</italic>., 2018[<xref rid="R22" ref-type="bibr">22</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Parra <italic toggle="yes">et al</italic>., 2019[<xref rid="R20" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">**</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>., 2017[<xref rid="R21" ref-type="bibr">21</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6</td></tr></tbody></table></table-wrap><p>PED ro scale, as shown in <xref rid="IJO.IJO_1322_23-T2" ref-type="table">Table 2</xref>, was employed to assess one randomized controlled trial study by Ting <italic toggle="yes">et al</italic>. (2018).[<xref rid="R19" ref-type="bibr">19</xref>] The study was a single-blind randomized controlled trial in which only the participants were blinded to their group allocation. The therapists who administered the intervention and the assessor who measured the outcome were not, hence a possible source of bias. The study satisfied other scale criteria and exhibited good reliability.</p><table-wrap position="float" id="IJO.IJO_1322_23-T2"><label>Table 2</label><caption><p>PEDro scale</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="5" rowspan="1">Ting <italic toggle="yes">et al</italic>., 2018[<xref rid="R19" ref-type="bibr">19</xref>]</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Eligibility criteria were specified</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Individuals aged 40&#x02013;85 years old, with OAG (&#x02265; Shaffer grade 2), inadequately controlled glaucoma and/or IOP on medical therapy; visually significant cataract with BCVA &#x02264;20/30</td></tr><tr><td align="left" rowspan="1" colspan="1">Subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which treatments were received)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Block randomization was performed</td></tr><tr><td align="left" rowspan="1" colspan="1">Allocation was concealed</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Randomization was done by the study coordinator to blind participants</td></tr><tr><td align="left" rowspan="1" colspan="1">The groups were similar at baseline regarding the most important prognostic indicators.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline IOP in both groups are not statistically significant (Phaco-AIT (Ab interno trabeculectomy or Trabectome) vs. Phaco-Trab, 20 vs. 23.1, <italic toggle="yes">P=</italic>0.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">There was blinding of all subjects.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">There was blinding of study participants</td></tr><tr><td align="left" rowspan="1" colspan="1">There was blinding of all therapists who administered the therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">There was blinding of all assessors who measured at least one key outcome</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Measures of at least one key outcome were obtained from more than 85% of the subjects initially allocated to groups.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Measurements were obtained on all subjects</td></tr><tr><td align="left" rowspan="1" colspan="1">All subjects for whom outcome measures were available received the treatment or control condition as allocated; where this was not the case, data for at least one key outcome was analyzed by intention to treat</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">All subjects received treatment according to the group allocated</td></tr><tr><td align="left" rowspan="1" colspan="1">The results of between-group statistical comparisons are reported for at least one key outcome</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Statistical comparisons are reported on key outcomes</td></tr><tr><td align="left" rowspan="1" colspan="1">The study provides both point measures and measures of variability for at least one key outcome</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9/11</td></tr></tbody></table></table-wrap></sec><sec id="sec2-7"><title>Data extraction</title><sec id="sec3-1"><title>Study characteristic</title><p>The characteristic summary of the included studies is presented in <xref rid="IJO.IJO_1322_23-T3" ref-type="table">Table 3</xref>, with a total of 306 OAG eyes from 276 individuals. Of this, only 140 and 119 eyes received a combination of phacoemulsification and trabeculectomy (Phaco-Trab) or MIGS (Phaco-MIGS), respectively. Thus, a total of 259 eyes were analyzed in this study. The included studies&#x02019; most common OAG diagnoses were POAG and pseudoexfoliative glaucoma (PEG). One retrospective cohort study (Parra <italic toggle="yes">et al</italic>.), one case-control study (Lau <italic toggle="yes">et al</italic>.), one case series study (T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.), and one randomized controlled trial (Ting <italic toggle="yes">et al</italic>.) were included, all published between 2017 and 2019. All studies performed phacoemulsification combined with trabeculectomy (Phaco-Trab) or phacoemulsification and MIGS (Phaco-MIGS). The MIGS procedure discussed in this review included endocyclophotocoagulation, <italic toggle="yes">ab interno</italic> trabeculectomy, Xen gel implant, and Excimer laser trabeculostomy.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>]</p><table-wrap position="float" id="IJO.IJO_1322_23-T3"><label>Table 3</label><caption><p>Characteristics of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Population</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Intervention</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">IOP definition of qualified success</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Follow up period</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Risk-of-bias scoring</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Randomized controlled trial</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PEDro scale (/11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ting <italic toggle="yes">et al</italic>.[<xref rid="R19" ref-type="bibr">19</xref>]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">19 eyes from 19 patients with open-angle glaucoma (Shaffer grade &#x02265;2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ab interno trabeculectomy (Trabectome) trabeculectomy with mitomycin C combined with phacoemulsification</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02264;21 mmHg or &#x02265;20% reduction from baseline IOP</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1, 3, 6, and 12 months</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Descriptive studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Newcastle&#x02013;Ottawa scale (/9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lau <italic toggle="yes">et al</italic>.[<xref rid="R22" ref-type="bibr">22</xref>]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">53 eyes of 53 patients with open-angle glaucoma</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Phaco-ECP (Endoscopic Cyclophotocoagulation) vs. Phaco-trab</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02264;15 mmHg or &#x02265;30% reduction from baseline</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 months</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Parra <italic toggle="yes">et al</italic>.[<xref rid="R20" ref-type="bibr">20</xref>]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">74 eyes with open-angle glaucoma</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Phaco-Xen (XEN Implant) vs. Phaco-trab</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IOP &#x02265;6 and &#x02264;16 mmHg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 day, 1 week (&#x000b1;2 days), 1 month (&#x000b1;1 week), 3 months (&#x000b1;2 weeks), 6 months (&#x000b1;2 weeks), 12 months (&#x000b1;1 month)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.[<xref rid="R21" ref-type="bibr">21</xref>]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">113 eyes from 113 patients with open-angle glaucoma (Shaffer 3 or 4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Phaco-ELT (Excimer laser trabeculotomy) vs. Phaco-Trab</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"> &#x02264;21 mmHg or &#x02265;20% IOP reduction from baseline</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 year, 4 years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6</td></tr></tbody></table></table-wrap><p>In our review, follow-up ranged from 1 day to 4 years post procedure. Lau <italic toggle="yes">et al</italic>. conducted a single follow-up assessment at 6 months post surgery, In contrast, Parra <italic toggle="yes">et al</italic>. did the most extensive follow-up assessment at 1 day, 1 week, and 1, 3, 6, and 12 months post intervention.[<xref rid="R20" ref-type="bibr">20</xref><xref rid="R22" ref-type="bibr">22</xref>] The longest follow-up period was by T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>., in which the patients were followed up to 4 years post procedure.[<xref rid="R21" ref-type="bibr">21</xref>]</p><p>Success criteria for IOP reduction differed between the studies included. Ting <italic toggle="yes">et al</italic>. and T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>. defined successful IOP reduction as IOP &#x02264;21 mmHg or a drop of at least 20% from baseline.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R21" ref-type="bibr">21</xref>] Lau <italic toggle="yes">et al</italic>. used a cutoff of &#x02264;15 mmHg or &#x02265;30% reduction from baseline, while Parra <italic toggle="yes">et al</italic>. defined success as IOP &#x02264;16 mmHg postoperative without antiglaucomatous medication.[<xref rid="R20" ref-type="bibr">20</xref><xref rid="R22" ref-type="bibr">22</xref>]</p></sec><sec id="sec3-2"><title>Baseline IOP measurement</title><p>Prior to treatment, IOP was measured in all studies to ascertain the difference in baseline IOP, as shown in <xref rid="IJO.IJO_1322_23-T4" ref-type="table">Table 4</xref>. Three studies used Goldmann applanation tonometry to measure IOP (Ting <italic toggle="yes">et al</italic>., Lau <italic toggle="yes">et al</italic>., and T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.).[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] Ting <italic toggle="yes">et al</italic>., in particular, recorded IOP measurements from the mean of two consecutive measurements.[<xref rid="R19" ref-type="bibr">19</xref>] No description was given by Parra <italic toggle="yes">et al</italic>. on the method used for measuring IOP.[<xref rid="R20" ref-type="bibr">20</xref>] Baseline IOP in the MIGS group showed a lower trend in comparison to the trabeculectomy group, and this difference was statistically significant (<italic toggle="yes">P</italic> &#x0003c; 0.05) except in the study by Ting <italic toggle="yes">et al</italic>. (20 mmHg vs. 23.1 mmHg, <italic toggle="yes">P</italic> = 0.22).[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref>]</p><table-wrap position="float" id="IJO.IJO_1322_23-T4"><label>Table 4</label><caption><p>IOP at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1"/><th align="left" rowspan="2" colspan="1">Method of measurement</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Baseline IOP (mmHg)<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Phaco-MIGS</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Phaco-Trab</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ting <italic toggle="yes">et al</italic>.[<xref rid="R19" ref-type="bibr">19</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Goldmann applanation tonometry, recorded as the mean of two consecutive measurements.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">23.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Lau <italic toggle="yes">et al</italic>.*[<xref rid="R22" ref-type="bibr">22</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Goldmann applanation tonometry.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Parra <italic toggle="yes">et al</italic>.[<xref rid="R20" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18.0&#x000b1;4.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20.0&#x000b1;4.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.0765</td></tr><tr><td align="left" rowspan="1" colspan="1">T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.[<xref rid="R21" ref-type="bibr">21</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Goldmann applanation tonometry</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">19.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">22.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>*IOPs are expressed in median</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-3"><title>Mean IOP during follow-up</title><p>Only two studies reported IOP points during follow-up. Ting <italic toggle="yes">et al</italic>. reported no significant difference in mean IOP between the Phaco-AIT group and the Phaco-Trab group at 6 months (17.5 mmHg vs. 16.0 mmHg, <italic toggle="yes">P</italic> = 0.54) and 12 months follow-up (16.8 mmHg vs. 17.1 mmHg, <italic toggle="yes">P</italic> = 0.57).[<xref rid="R19" ref-type="bibr">19</xref>] Interestingly, in a study by T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>., the Phaco-Trab group showed higher IOP at baseline in comparison to the Phaco-ELT group (22.8 mmHg vs. 19.0 mmHg, <italic toggle="yes">P</italic> &#x0003c; 0.001), whereas at 1-year follow-up, the Phaco-Trab group showed lower median IOP (13.0 mmHg vs. 15.0 mmHg, <italic toggle="yes">P</italic> &#x0003c; 0.001). However, these differences diminished at 4 years follow-up, where both groups had a median IOP of 14.0 mmHg (<italic toggle="yes">P</italic> = 0.097)[<xref rid="R21" ref-type="bibr">21</xref>] [<xref rid="IJO.IJO_1322_23-T5" ref-type="table">Table 5</xref>].</p><table-wrap position="float" id="IJO.IJO_1322_23-T5"><label>Table 5</label><caption><p>Mean IOP</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Author</th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">Time of follow-up</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">IOP (mmHg)<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Phaco-MIGS</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Phaco-Trab</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Phaco-AIT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ting <italic toggle="yes">et al</italic>.[<xref rid="R19" ref-type="bibr">19</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17.5&#x000b1;3.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16.0&#x000b1;6.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16.8&#x000b1;2.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17.1&#x000b1;5.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-ELT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.*[<xref rid="R21" ref-type="bibr">21</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 year</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">13.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 years</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.097</td></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>*Data presented as median</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-4"><title>IOP change</title><p>Four studies reported IOP evolution between the Phaco-MIGS and Phaco-Trab groups throughout their follow-up periods. Neither group had a statistically significant difference in each follow-up visit performed by Lau <italic toggle="yes">et al</italic>. and Ting <italic toggle="yes">et al</italic>.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R22" ref-type="bibr">22</xref>] Studies by Parra <italic toggle="yes">et al</italic>. and T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>. found a statistically significant difference in mean IOP reduction between the Phaco-MIGS and Phaco-trab groups at postoperative follow-up visits.[<xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref>] However, no significant difference in mean IOP changes was reported after 6 months (&#x02212;4.3 mmHg vs. &#x02212;7.1 mmHg, <italic toggle="yes">P</italic> = 0.36) in a study by Parra <italic toggle="yes">et al</italic>.[<xref rid="R20" ref-type="bibr">20</xref>] All studies reported statistically significant IOP reduction postoperative compared to baseline (<italic toggle="yes">P</italic> &#x0003c; 0.05)[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] [<xref rid="IJO.IJO_1322_23-T6" ref-type="table">Table 6</xref>].</p><table-wrap position="float" id="IJO.IJO_1322_23-T6"><label>Table 6</label><caption><p>IOP reduction during follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">Time of follow-up</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">IOP (mmHg)<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Phaco-MIGS</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Phaco-Trab</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Phaco-ECP vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lau <italic toggle="yes">et al</italic>.[<xref rid="R22" ref-type="bibr">22</xref>] (mean)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.137</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-AIT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ting <italic toggle="yes">et al</italic>.[<xref rid="R19" ref-type="bibr">19</xref>] (mean, SD)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;2.8 &#x000b1; 3.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;7.4 &#x000b1; 9.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;2.7 &#x000b1; 5.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;6.4 &#x000b1; 8.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-Xen vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Parra <italic toggle="yes">et al</italic>. (mean, 95%CI)[<xref rid="R20" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 day</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;5.5 (&#x02212;9.2, &#x02212;1.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;10.4 (&#x02212;14.7, &#x02212;6.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.0122</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 week</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;5.6 (&#x02212;8.2, &#x02212;3.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212; 10.3 (&#x02212;14.6, &#x02212;6.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.0173</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 month</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;3.3 (&#x02212;5.9, &#x02212;0.6)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;8.4 (&#x02212;11.7, &#x02212;5.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.0083</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;2.8 (&#x02212;5.5,&#x02212;0.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;7.6 (&#x02212;11.4, &#x02212;3.9)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.0093</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;4.3 (&#x02212;6.7, &#x02212;1.9)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;7.1 (&#x02212;10.2, &#x02212;4.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.3623</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;3.5 (&#x02212;5.8, &#x02212;1.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;7.3 (&#x02212;10.7, &#x02212;4.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.0508</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-ELT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.[<xref rid="R21" ref-type="bibr">21</xref>] (mean, SD)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;4 (5.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;9.8 (4.09)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 years</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;5 (5.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02212;8.8 (4.05)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></sec><sec id="sec3-5"><title>Number of antiglaucomatous medication</title><p><xref rid="IJO.IJO_1322_23-T7" ref-type="table">Tables 7</xref> and <xref rid="IJO.IJO_1322_23-T8" ref-type="table">8</xref> summarize the study findings on the reduction and number of antiglaucomatous medications postoperatively. All four studies reported a significant reduction in antiglaucomatous medication in both groups at postoperative follow-up.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] Two studies reported a comparable number of antiglaucomatous medications used postoperatively in the Phaco-MIGS and Phaco-Trab groups.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref>] This differed from the T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>. study, where the median amount of drugs used after Phaco-ELT was higher compared with after the Phaco-Trab (1 vs. 0, <italic toggle="yes">P</italic> = &#x0003c;0.001) in each of the follow-up visits (1 and 4 years postoperatively).[<xref rid="R21" ref-type="bibr">21</xref>] At 6 months follow-up, Lau <italic toggle="yes">et al</italic>. found that the reduction of antiglaucomatous medication number in the Phaco-Trab group was significantly higher than in the Phaco-ECP group (4 vs. 1, <italic toggle="yes">P</italic> = 0.001).[<xref rid="R22" ref-type="bibr">22</xref>]</p><table-wrap position="float" id="IJO.IJO_1322_23-T7"><label>Table 7</label><caption><p>Antiglaucomatous medication used</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">Time of follow-up</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Number of antiglaucomatous medication<hr/></th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Phaco-MIGS</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Phaco-Trab</th><th align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Phaco-Xen vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Parra <italic toggle="yes">et al</italic>.[<xref rid="R20" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">baseline</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.1&#x000b1;0.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.1&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-AIT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ting <italic toggle="yes">et al</italic>.[<xref rid="R19" ref-type="bibr">19</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">baseline</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.78&#x000b1;1.39</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.38&#x000b1;0.74</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.44&#x000b1;0.88</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.75&#x000b1;0.89</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-ELT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.*[<xref rid="R21" ref-type="bibr">21</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">baseline</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.722</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 year</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 years</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TF-F3"><p>*Presented in median</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="IJO.IJO_1322_23-T8"><label>Table 8</label><caption><p>Reduction of medication</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">Time of follow-up</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Number of antiglaucomatous medication reduction<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Phaco-MIGS</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Phaco-Trab</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Phaco-ECP vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lau <italic toggle="yes">et al</italic>.[<xref rid="R22" ref-type="bibr">22</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.001</td></tr></tbody></table></table-wrap></sec><sec id="sec3-6"><title>Success rate</title><p><xref rid="IJO.IJO_1322_23-T9" ref-type="table">Table 9</xref> summarizes the success rate in both treatment groups from the four included studies. Qualified success was awarded if a defined target IOP criteria [<xref rid="IJO.IJO_1322_23-T3" ref-type="table">Table 3</xref>] was achieved and maintained with or without medication in the study participants, whereas in complete success, the target IOP has to be achieved without medication use. Overall, the Phaco-Trab group showed a higher trend of success in comparison to the Phaco-MIGS group for both qualified and complete criteria, although not always statistically significant.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] At 1-year and 4-year follow-ups, T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>. reported a significantly higher percentage of success in the Phaco-Trab group than in the Phaco-ELT group (<italic toggle="yes">P</italic> &#x0003c; 0.001).[<xref rid="R21" ref-type="bibr">21</xref>] In contrast, when Phaco-AIT was compared with Phaco-Trab, Phaco-AIT demonstrated no statistically significant difference in qualified and complete success (<italic toggle="yes">P</italic> = 0.14).[<xref rid="R19" ref-type="bibr">19</xref>] Lau <italic toggle="yes">et al</italic>. reported a comparable qualified success rate at 6-month follow-ups (76.2% vs. 71%, <italic toggle="yes">P</italic> = 0.677) but a statistically higher complete success for the Phaco-Trab group (38.1% vs. 3.2%, <italic toggle="yes">P</italic> = 0.002).[<xref rid="R22" ref-type="bibr">22</xref>] Parra <italic toggle="yes">et al</italic>. did not report their qualified success findings and found a significantly higher complete success in the Phaco-Trab group (84.6% vs. 62.5%, <italic toggle="yes">P</italic> = &#x0003c;0.05).[<xref rid="R20" ref-type="bibr">20</xref>]</p><table-wrap position="float" id="IJO.IJO_1322_23-T9"><label>Table 9</label><caption><p>Success rate during follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="center" rowspan="2" colspan="1"/><th align="left" rowspan="2" colspan="1">Criteria</th><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Success rate (%)<hr/></th><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Phaco-MIGS</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Phaco-Trab</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Phaco-ECP vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lau <italic toggle="yes">et al</italic>.*[<xref rid="R22" ref-type="bibr">22</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Qualified success<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">76.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.677</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Complete success<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">38.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-AIT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ting <italic toggle="yes">et al</italic>.<sup>&#x02020;</sup>[<xref rid="R19" ref-type="bibr">19</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Qualified success<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">37.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="2" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Complete success<sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-ELT vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.<sup>&#x02020;</sup>[<xref rid="R21" ref-type="bibr">21</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Qualified success</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">47<sup>a</sup>, 34<sup>b</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">95<sup>a</sup>, 89<sup>b</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Complete success</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">18<sup>a</sup>, 9<sup>b</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">90<sup>a</sup>, 75<sup>b</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Phaco-XEN vs. Phaco-Trab</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Parra <italic toggle="yes">et al</italic>.[<xref rid="R20" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Qualified success</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Complete success</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">62.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">84.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TF-F4"><p>a: at 1 year, b: at 4 years, *&#x02264;15 mmHg/&#x02265;30% reduction from baseline, <sup>&#x02020;</sup>&#x02264;21 mmHg/&#x02265;20% reduction from baseline</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-7"><title>Complication</title><p>Ting <italic toggle="yes">et al</italic>. and T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>. reported that most early postoperative period complications were IOP spikes and hypotony.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R21" ref-type="bibr">21</xref>] IOP spikes were more common in the Phaco-MIGS group than in the Phaco-Trab group in studies; However, Ting <italic toggle="yes">et al</italic>. found that the difference was not statistically significant (50% vs. 33%, <italic toggle="yes">P</italic> &#x0003e; 0.05).[<xref rid="R19" ref-type="bibr">19</xref>] T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>. only found IOP spike incidence in the Phaco-MIGS group (10% vs. 0%, <italic toggle="yes">P</italic> = 0.017).[<xref rid="R21" ref-type="bibr">21</xref>] Conversely, hypotony in the early postoperative period was more common in the Phaco-Trab group in both studies. However, only T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>. found this to be statistically significant (22% vs. 4%, <italic toggle="yes">P</italic> &#x0003c; 0.001). Overall, Ting <italic toggle="yes">et al</italic>. disclosed that the incidence of early postoperative complications and late postoperative complications in both groups were not significantly different. Severe early postoperative complications, choroidal effusion, and hypotony maculopathy were seen only in the Phaco-Trab group.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R21" ref-type="bibr">21</xref>]</p></sec></sec></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>An externo trabeculectomy with antifibrotic agents is the favored surgical intervention for a patient with OAG and cataract when phacoemulsification alone is deemed insufficient to reach the target IOP. It was first successfully described by Cairns <italic toggle="yes">et al</italic>. in 1968. Since then, there have been several modifications to the procedure to increase its success rate, such as using antifibrotic agents to prevent fibrovascular ingrowth.[<xref rid="R23" ref-type="bibr">23</xref>] However, this procedure is invasive and carries many risks, such as choroidal effusion, endophthalmitis, and hypotony maculopathy.[<xref rid="R12" ref-type="bibr">12</xref>]</p><p>MIGS is a relatively new procedure that might be an alternative to trabeculectomy with better safety properties. Yet, studies on MIGS in combination with Phaco for patients with OAG are sparse. In this review, we included four studies published between 2017 and 2019; all studies were examined for risk of bias by using appropriate tools and showed moderate to excellent quality.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>]</p><p>All four included studies noted a significant reduction of IOP compared to baseline and comparable IOP reduction between treatment groups at each follow-up, except for the Phaco-XEN group in the study by Parra <italic toggle="yes">et al</italic>., which reported a significant difference between treatment groups during early postoperative follow-up to 3 months, which became comparable at 6 and 12 months follow-up.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] Previous meta-analysis done by Wang <italic toggle="yes">et al</italic>. of 1602 eyes comparing the effectiveness of Xen implant either alone or in combination with phacoemulsification against trabeculectomy reported a similar finding in which both procedures managed to achieve a significant reduction of antiglaucomatous medication and found that the IOP was comparable.[<xref rid="R24" ref-type="bibr">24</xref>] The efficacy of XEN in combination with phacoemulsification might be influenced by the viscoelastic used, where the residues might cause differences in the early postoperative period and gradually diminish.[<xref rid="R24" ref-type="bibr">24</xref>] This was also seen in the study by Parra <italic toggle="yes">et al</italic>., wherein the mean IOP reductions between Phaco-XEN and Phaco-Trab differed significantly up to the 3<sup>rd</sup>-month follow-up but remained similar from the 6<sup>th</sup>-month follow-up onward (<italic toggle="yes">P</italic> &#x0003e; 0.05).[<xref rid="R20" ref-type="bibr">20</xref>] XEN implant works similarly to trabeculectomy to reduce IOP by shunting the aqueous outflow toward subconjunctival space. Interestingly, XEN possesses several benefits compared with trabeculectomy due to its simpler procedure, smaller incision, stable anterior chamber, less postoperative inflammation, and most importantly, not causing conjunctival injury or scar.[<xref rid="R24" ref-type="bibr">24</xref>] With similar efficacy and fewer complications reported, Phaco-XEN might be a promising alternative to treat OAG less invasively.</p><p>In our study, the success rates of the Phaco-AIT group reported by Ting <italic toggle="yes">et al</italic>. at 1-year follow-up were lower (40%) than in previous studies.[<xref rid="R19" ref-type="bibr">19</xref>] A possible cause for this is insufficient engagement or reapproximation with the footplate, in addition to other factors such as lower baseline IOP, younger age, and BMI &#x0003e;25 kg/m<sup>2</sup>.[<xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref>] In contrast, our included comparison of Phaco-ECP and Phaco-Trab by Lau <italic toggle="yes">et al</italic>. revealed a comparable IOP reduction and success rate between the two groups (<italic toggle="yes">P</italic> &#x0003e; 0.05).[<xref rid="R21" ref-type="bibr">21</xref>] This finding aligns with the only RCT ever done comparing the two interventions of 58 eyes by Gayton <italic toggle="yes">et al</italic>. In addition to similar IOP reduction and success rate profile, they reported a similar antiglaucomatous medication reduction.[<xref rid="R27" ref-type="bibr">27</xref>]</p><p>According to the study by T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>., Phaco-Trab showed significantly higher qualified and complete success rates at 1 and 4 years postoperatively than Phaco-ELT. Despite this, their other findings revealed a significant IOP reduction from baseline in eyes having Phaco-ELT, with constant results after a year of follow-up, and no severe complication was reported except for a mild anterior chamber reaction.[<xref rid="R28" ref-type="bibr">28</xref>] This is corroborated by a review by Durr <italic toggle="yes">et al</italic>. showing significant IOP reduction with minimal complications, including IOP spikes and hyphema, which can be resolved without complicated measures.[<xref rid="R29" ref-type="bibr">29</xref>]</p><p>The use of antifibrotic agents in trabeculectomy to increase its success rate may lead to an increased incidence of bleb-related infections.[<xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref><xref rid="R30" ref-type="bibr">30</xref><xref rid="R31" ref-type="bibr">31</xref>] Studies have reported an incidence rate of endophthalmitis after filtration procedures with antifibrotic agents between 1.1% and 3%.[<xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref><xref rid="R31" ref-type="bibr">31</xref>] A thinner bleb wall due to the use of antifibrotic agents may lead to bleb leak, which is a predisposing factor for infection from the transconjunctival spread of the organism.[<xref rid="R30" ref-type="bibr">30</xref>]</p><p>Overall, in our included studies, we found that the Phaco-MIGS group reported fewer complications compared to the Phaco-Trab. Possibly because of a restricted number of studies and eyes, no post-intervention infection was reported in both groups from the four studies included.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] Although the report of endophthalmitis post Phaco-MIGS is scarce compared to Phaco-Trab, previously, severe endophthalmitis had been reported in a patient who underwent Phaco-MIGS using IStent injection.[<xref rid="R32" ref-type="bibr">32</xref>] Nevertheless, the risk of infection must be acknowledged by surgeons in either intervention.</p><p>Overall, the Phaco-MIGS group reported fewer complications, such as hypotony, choroidal hemorrhage, inflammation, and lower anterior chamber reaction incidence, than the Phaco-Trab group, which aligns with previous studies.[<xref rid="R27" ref-type="bibr">27</xref><xref rid="R33" ref-type="bibr">33</xref><xref rid="R34" ref-type="bibr">34</xref>] In the Phaco-AIT group, there is no bleb formation and no device is left in the eye, thus reducing the perpetual risk of infection. The low incidence of severe complications reported in the study by Ting <italic toggle="yes">et al</italic>. was consistent with previous studies, in which out of approximately 10,902 reported cases, hypotony made up 0.09% of all reported cases, choroidal hemorrhage 0.01%, and endophthalmitis 0.01%.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R33" ref-type="bibr">33</xref><xref rid="R34" ref-type="bibr">34</xref>]</p><p>Due to the limited number of available studies on the topic, the population in our included studies was pretty small at 259 OAG eyes from four studies with different types of MIGS.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] There was also a varying definition of target IOP used as success criteria between studies: whereas two studies (Ting <italic toggle="yes">et al</italic>. and T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>.) used &#x02264;21 mmHg or &#x02265;20% reduction from baseline based on a prior study by Gedde <italic toggle="yes">et al</italic>., one study by Lau <italic toggle="yes">et al</italic>. used &#x02264;15 mmHg or &#x02265;30% reduction from baseline as their criteria.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R35" ref-type="bibr">35</xref>] These factors might influence the interpretation of the overall success rates reported in our study and imply that the success rate in the Lau <italic toggle="yes">et al</italic>. study might be higher than reported.[<xref rid="R22" ref-type="bibr">22</xref>] IOP baselines differed between the Phaco-MIGS and Phaco-Trab eyes in the study by Lau <italic toggle="yes">et al</italic>. and T&#x000f6;teberg-Harms <italic toggle="yes">et al</italic>., thus affecting the result interpretation.[<xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] There was a risk of population bias in studies included, with a homogenous racial profile as most participants were Caucasians, while Asians were rarely reported. The differences in conjunctival cell profile and racial differences might influence the pigmentation of ciliary epithelium, which may affect the result of the MIGS procedure. This racial influence has also been studied by Husain R <italic toggle="yes">et al</italic>. but reflects its effect only on trabeculectomy eyes.[<xref rid="R36" ref-type="bibr">36</xref>]</p><p>Furthermore, RCTs should be done for each type of MIGS available in combination with phacoemulsification, comparing it to Phaco-Trab. Future studies should include more Asian populations with robust IOP criteria and OAG definition at baseline.</p></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>Phaco-MIGS, particularly Trabectome, offer a good option for individuals with OAG and concomitant cataracts, showing a comparable outcome to Phaco-Trab. Complications are comparable in both groups, although severe complications such as hypotony, maculopathy, and choroidal effusion were only observed in the Phaco-Trab group. Further studies through RCT are needed to validate these findings.</p><sec sec-type="funding-statement" id="sec2-8"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" id="sec2-9"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schuster</surname><given-names>AK</given-names></name>
<name><surname>Erb</surname><given-names>C</given-names></name>
<name><surname>Hoffmann</surname><given-names>EM</given-names></name>
<name><surname>Dietlein</surname><given-names>T</given-names></name>
<name><surname>Pfeiffer</surname><given-names>N</given-names></name></person-group><article-title>The diagnosis and treatment of glaucoma</article-title><source>Dtsch Arztebl Int</source><year>2020</year><volume>117</volume><fpage>225</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">32343668</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aref</surname><given-names>AA</given-names></name>
<name><surname>Moore</surname><given-names>DB</given-names></name>
<name><surname>Conner</surname><given-names>I</given-names></name>
<name><surname>Rooney</surname><given-names>DM</given-names></name></person-group><article-title>Glaucoma in the developing world</article-title><source>Am Acad Ophthalmol</source><year>2023</year><comment>Available from: <uri xlink:href="https://eyewiki.aao.org/Glaucoma_in_the_Developing_World#:~:text=In%20developing%20countries%2C%20those%20affected,risk%20of%20progressing%20to%20blindness">https://eyewiki.aao.org/Glaucoma_in_the_Developing_World#:~:text=In%20developing%20countries%2C%20those%20affected, risk%20of%20progressing%20to%20blindness</uri> [Last accessed on 2023 Sep]</comment></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tham</surname><given-names>YC</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Wong</surname><given-names>TY</given-names></name>
<name><surname>Quigley</surname><given-names>HA</given-names></name>
<name><surname>Aung</surname><given-names>T</given-names></name>
<name><surname>Cheng</surname><given-names>CY</given-names></name></person-group><article-title>Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis</article-title><source>Ophthalmology</source><year>2014</year><volume>121</volume><fpage>2081</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">24974815</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study</collab>
</person-group><article-title>Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study</article-title><source>Lancet Glob Health</source><year>2021</year><volume>9</volume><fpage>e144</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">33275949</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rudnicka</surname><given-names>AR</given-names></name>
<name><surname>Mt-Isa</surname><given-names>S</given-names></name>
<name><surname>Owen</surname><given-names>CG</given-names></name>
<name><surname>Cook</surname><given-names>DG</given-names></name>
<name><surname>Ashby</surname><given-names>D</given-names></name></person-group><article-title>Variations in primary open-angle glaucoma prevalence by age, gender, and race: A Bayesian meta-analysis</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>4254</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17003413</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nowak</surname><given-names>MS</given-names></name>
<name><surname>Smigielski</surname><given-names>J</given-names></name></person-group><article-title>The prevalence of age-related eye diseases and cataract surgery among older adults in the city of Lodz, Poland</article-title><source>J Ophthalmol</source><year>2015</year><volume>2015</volume><fpage>605814</fpage><pub-id pub-id-type="pmid">25789169</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hashemi</surname><given-names>H</given-names></name>
<name><surname>Mohammadi</surname><given-names>M</given-names></name>
<name><surname>Zandvakil</surname><given-names>N</given-names></name>
<name><surname>Khabazkhoob</surname><given-names>M</given-names></name>
<name><surname>Emamian</surname><given-names>MH</given-names></name>
<name><surname>Shariati</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Prevalence and risk factors of glaucoma in an adult population from Shahroud, Iran</article-title><source>J Curr Ophthalmol</source><year>2018</year><volume>31</volume><fpage>366</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">31844784</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>The Global Health Observatory World Health Organization</collab>
</person-group><article-title>Global Health Estimates: Life expectancy and healthy life expectancy</article-title><publisher-loc>Geneva</publisher-loc><publisher-name>Department of Data and Analytics. World Health Organization</publisher-name><year>2020</year></element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>World Report on Vision</article-title><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><year>2019</year></element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>ML</given-names></name>
<name><surname>Hirunyachote</surname><given-names>P</given-names></name>
<name><surname>Jampel</surname><given-names>H</given-names></name></person-group><article-title>Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><volume>2015</volume><fpage>CD008671</fpage><pub-id pub-id-type="pmid">26171900</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wisner</surname><given-names>DM</given-names></name>
<name><surname>Stelzner</surname><given-names>SK</given-names></name>
<name><surname>Brown</surname><given-names>EN</given-names></name>
<name><surname>Al-Aswad</surname><given-names>L</given-names></name>
<name><surname>Jindal</surname><given-names>AP</given-names></name>
<name><surname>Feldman</surname><given-names>BH</given-names></name>
<etal/></person-group><article-title>Techniques for combined cataract and filtering glaucoma surgery</article-title><source>American Academy of Ophthalmology</source><year>2023</year><comment>Available from: <uri xlink:href="https://eyewiki.aao.org/Techniques_for_Combined_Cataract_and_Filtering_Glaucoma_Surgery">https://eyewiki.aao.org/Techniques_for_Combined_Cataract_and_Filtering_Glaucoma_Surgery</uri> [Last accessed on Sep 2023]</comment></element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirwan</surname><given-names>JF</given-names></name>
<name><surname>Lockwood</surname><given-names>AJ</given-names></name>
<name><surname>Shah</surname><given-names>P</given-names></name>
<name><surname>Macleod</surname><given-names>A</given-names></name>
<name><surname>Broadway</surname><given-names>DC</given-names></name>
<name><surname>King</surname><given-names>AJ</given-names></name>
<etal/></person-group><article-title>Trabeculectomy in the 21<sup>st</sup> century: A multicenter analysis</article-title><source>Ophthalmology</source><year>2013</year><volume>120</volume><fpage>2532</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24070811</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>DZ</given-names></name>
<name><surname>Sng</surname><given-names>CCA</given-names></name></person-group><article-title>Safety and efficacy of microinvasive glaucoma surgery</article-title><source>J Ophthalmol</source><year>2017</year><volume>2017</volume><fpage>3182935</fpage><pub-id pub-id-type="pmid">28512578</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schehlein</surname><given-names>EM</given-names></name>
<name><surname>Kaleem</surname><given-names>MA</given-names></name>
<name><surname>Swamy</surname><given-names>R</given-names></name>
<name><surname>Saeedi</surname><given-names>OJ</given-names></name></person-group><article-title>Microinvasive glaucoma surgery: An evidence-based assessment</article-title><source>Expert Rev Ophthalmol</source><year>2017</year><volume>12</volume><fpage>331</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">30026790</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aref</surname><given-names>AA</given-names></name>
<name><surname>Tripathy</surname><given-names>K</given-names></name>
<name><surname>Ridha</surname><given-names>F</given-names></name>
<name><surname>Ertel</surname><given-names>MK</given-names></name>
<name><surname>Eliassi-Rad</surname><given-names>B</given-names></name>
<name><surname>Seibold</surname><given-names>LK</given-names></name>
<etal/></person-group><article-title>Microinvasive Glaucoma Surgery (MIGS)</article-title><source>American Academy of Ophthalmology;</source><year>2023</year><comment>Available from: <uri xlink:href="https://eyewiki.aao.org/Microinvasive_Glaucoma_Surgery_(MIGS)">https://eyewiki.aao.org/Microinvasive_Glaucoma_Surgery_(MIGS)</uri> [Last accessed on Sep 2023]</comment></element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Konopi&#x00144;ska</surname><given-names>J</given-names></name>
<name><surname>Lewczuk</surname><given-names>K</given-names></name>
<name><surname>Jab&#x00142;o&#x00144;ska</surname><given-names>J</given-names></name>
<name><surname>Mariak</surname><given-names>Z</given-names></name>
<name><surname>R&#x00119;kas</surname><given-names>M</given-names></name></person-group><article-title>Microinvasive glaucoma surgery: A review of Schlemm&#x02019;s canal-based procedures</article-title><source>Clin Ophthalmol</source><year>2021</year><volume>15</volume><fpage>1109</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">33737802</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><article-title>Newcastle-Ottawa Quality Assessment form for cohort studies</article-title><year>2023</year><comment>Available from: <uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK115843/bin/appe-fm3.pdf">https://www.ncbi.nlm.nih.gov/books/NBK115843/bin/appe-fm3.pdf</uri></comment></element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><article-title>PEDro scale</article-title><comment>Available from: <uri xlink:href="https://pedro.org.au/english/resources/pedro-scale/">https://pedro.org.au/english/resources/pedro-scale/</uri></comment></element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ting</surname><given-names>JLM</given-names></name>
<name><surname>Rudnisky</surname><given-names>CJ</given-names></name>
<name><surname>Damji</surname><given-names>KF</given-names></name></person-group><article-title>Prospective randomized controlled trial of phaco-trabectome versus phaco-trabeculectomy in patients with open angle glaucoma</article-title><source>Can J Ophthalmol</source><year>2018</year><volume>53</volume><fpage>588</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">30502982</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marcos Parra</surname><given-names>MT</given-names></name>
<name><surname>Salinas L&#x000f3;pez</surname><given-names>JA</given-names></name>
<name><surname>L&#x000f3;pez Grau</surname><given-names>NS</given-names></name>
<name><surname>Ceausescu</surname><given-names>AM</given-names></name>
<name><surname>P&#x000e9;rez Santonja</surname><given-names>JJ</given-names></name></person-group><article-title>XEN implant device versus trabeculectomy, either alone or in combination with phacoemulsification, in open-angle glaucoma patients</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2019</year><volume>257</volume><fpage>1741</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">31093766</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>T&#x000f6;teberg-Harms</surname><given-names>M</given-names></name>
<name><surname>Wachtl</surname><given-names>J</given-names></name>
<name><surname>Schweier</surname><given-names>C</given-names></name>
<name><surname>Funk</surname><given-names>J</given-names></name>
<name><surname>Kniestedt</surname><given-names>C</given-names></name></person-group><article-title>Long-term efficacy of combined phacoemulsification plus trabeculectomy versus phacoemulsification plus excimer laser trabeculotomy</article-title><source>Klin Monbl Augenheilkd</source><year>2017</year><volume>234</volume><fpage>457</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">28264221</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lau</surname><given-names>CSL</given-names></name>
<name><surname>Chan</surname><given-names>JCW</given-names></name>
<name><surname>So</surname><given-names>SF</given-names></name>
<name><surname>Chan</surname><given-names>OCC</given-names></name>
<name><surname>Li</surname><given-names>KKW</given-names></name></person-group><article-title>Combined phacoendoscopic cyclophotocoagulation versus combined phacotrabeculectomy in the management of coexisting cataract and glaucoma: A comparative study</article-title><source>J Ophthalmol</source><year>2018</year><volume>2018</volume><fpage>5149154</fpage><pub-id pub-id-type="pmid">30647959</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cairns</surname><given-names>JE</given-names></name></person-group><article-title>Trabeculectomy. Preliminary report of a new method</article-title><source>Am J Ophthalmol</source><year>1968</year><volume>66</volume><fpage>673</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">4891876</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>B</given-names></name>
<name><surname>Leng</surname><given-names>X</given-names></name>
<name><surname>An</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Lu</surname><given-names>X</given-names></name></person-group><article-title>XEN gel implant with or without phacoemulsification for glaucoma: A systematic review and meta-analysis</article-title><source>Ann Transl Med</source><year>2020</year><volume>8</volume><fpage>1309</fpage><pub-id pub-id-type="pmid">33209889</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Higginbotham</surname><given-names>EJ</given-names></name>
<name><surname>Stevens</surname><given-names>RK</given-names></name>
<name><surname>Musch</surname><given-names>DC</given-names></name>
<name><surname>Karp</surname><given-names>KO</given-names></name>
<name><surname>Lichter</surname><given-names>PR</given-names></name>
<name><surname>Bergstrom</surname><given-names>TJ</given-names></name>
<etal/></person-group><article-title>Bleb-related endophthalmitis after trabeculectomy with mitomycin C</article-title><source>Ophthalmology</source><year>1996</year><volume>103</volume><fpage>650</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8618766</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greenfield</surname><given-names>DS</given-names></name>
<name><surname>Su&#x000f1;er</surname><given-names>IJ</given-names></name>
<name><surname>Miller</surname><given-names>MP</given-names></name>
<name><surname>Kangas</surname><given-names>TA</given-names></name>
<name><surname>Palmberg</surname><given-names>PF</given-names></name>
<name><surname>Flynn</surname><given-names>HW</given-names><suffix>Jr</suffix></name></person-group><article-title>Endophthalmitis after filtering surgery with mitomycin</article-title><source>Arch Ophthalmol</source><year>1996</year><volume>114</volume><fpage>943</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8694729</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gayton</surname><given-names>JL</given-names></name>
<name><surname>Van Der Karr</surname><given-names>M</given-names></name>
<name><surname>Sanders</surname><given-names>V</given-names></name></person-group><article-title>Combined cataract and glaucoma surgery: Trabeculectomy versus endoscopic laser cycloablation</article-title><source>J Cataract Refract Surg</source><year>1999</year><volume>25</volume><fpage>1214</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10476504</pub-id>
</element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>T&#x000f6;teberg-Harms</surname><given-names>M</given-names></name>
<name><surname>Hanson</surname><given-names>JV</given-names></name>
<name><surname>Funk</surname><given-names>J</given-names></name></person-group><article-title>Cataract surgery combined with excimer laser trabeculotomy to lower intraocular pressure: Effectiveness dependent on preoperative IOP</article-title><source>BMC Ophthalmol</source><year>2013</year><volume>13</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23360243</pub-id>
</element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Durr</surname><given-names>GM</given-names></name>
<name><surname>T&#x000f6;teberg-Harms</surname><given-names>M</given-names></name>
<name><surname>Lewis</surname><given-names>R</given-names></name>
<name><surname>Fea</surname><given-names>A</given-names></name>
<name><surname>Marolo</surname><given-names>P</given-names></name>
<name><surname>Ahmed</surname><given-names>IIK</given-names></name></person-group><article-title>Current review of excimer laser trabeculostomy</article-title><source>Eye Vis (Lond)</source><year>2020</year><volume>7</volume><fpage>24</fpage><pub-id pub-id-type="pmid">32391398</pub-id>
</element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Bleb-related infection: Clinical features and management</article-title><source>Taiwan J Ophthalmol</source><year>2012</year><volume>2</volume><fpage>2</fpage><lpage>5</lpage></element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razeghinejad</surname><given-names>MR</given-names></name>
<name><surname>Havens</surname><given-names>SJ</given-names></name>
<name><surname>Katz</surname><given-names>LJ</given-names></name></person-group><article-title>Trabeculectomy bleb-associated infections</article-title><source>Surv Ophthalmol</source><year>2017</year><volume>62</volume><fpage>591</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">28188728</pub-id>
</element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaves</surname><given-names>AC</given-names></name>
<name><surname>Grosinger</surname><given-names>AJ</given-names></name>
<name><surname>Ten Hulzen</surname><given-names>RD</given-names></name>
<name><surname>Stewart</surname><given-names>MW</given-names></name>
<name><surname>Dorairaj</surname><given-names>SK</given-names></name></person-group><article-title>Endophthalmitis following combined cataract extraction and placement of an iStent trabecular bypass device</article-title><source>Am J Ophthalmol Case Rep</source><year>2020</year><volume>20</volume><fpage>100830</fpage><pub-id pub-id-type="pmid">32875148</pub-id>
</element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaplowitz</surname><given-names>K</given-names></name>
<name><surname>Bussel</surname><given-names>II</given-names></name>
<name><surname>Honkanen</surname><given-names>R</given-names></name>
<name><surname>Schuman</surname><given-names>JS</given-names></name>
<name><surname>Loewen</surname><given-names>NA</given-names></name></person-group><article-title>Review and meta-analysis of ab-interno trabeculectomy outcomes</article-title><source>Br J Ophthalmol</source><year>2016</year><volume>100</volume><fpage>594</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">26733487</pub-id>
</element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Francis</surname><given-names>BA</given-names></name>
<name><surname>See</surname><given-names>RF</given-names></name>
<name><surname>Rao</surname><given-names>NA</given-names></name>
<name><surname>Minckler</surname><given-names>DS</given-names></name>
<name><surname>Baerveldt</surname><given-names>G</given-names></name></person-group><article-title>Ab interno trabeculectomy: Development of a novel device (Trabectome) and surgery for open-angle glaucoma</article-title><source>J Glaucoma</source><year>2006</year><volume>15</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">16378021</pub-id>
</element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gedde</surname><given-names>SJ</given-names></name>
<name><surname>Schiffman</surname><given-names>JC</given-names></name>
<name><surname>Feuer</surname><given-names>WJ</given-names></name>
<name><surname>Parrish</surname><given-names>RK</given-names><suffix>2nd</suffix></name>
<name><surname>Heuer</surname><given-names>DK</given-names></name>
<name><surname>Brandt</surname><given-names>JD</given-names></name>
<etal/></person-group><article-title>The tube versus trabeculectomy study: Design and baseline characteristics of study patients</article-title><source>Am J Ophthalmol</source><year>2005</year><volume>140</volume><fpage>275</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">16086949</pub-id>
</element-citation></ref><ref id="R36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Husain</surname><given-names>R</given-names></name>
<name><surname>Clarke</surname><given-names>JC</given-names></name>
<name><surname>Seah</surname><given-names>SK</given-names></name>
<name><surname>Khaw</surname><given-names>PT</given-names></name></person-group><article-title>A review of trabeculectomy in East Asian people--the influence of race</article-title><source>Eye (Lond)</source><year>2005</year><volume>19</volume><fpage>243</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15272288</pub-id>
</element-citation></ref></ref-list></back></article>